Computational Insight on Bioactive Compound Potential Activity of Kenitu (Chrysophyllum cainito L.) Leaves as PPAR-y Antagonist for Obesity
DOI:
https://doi.org/10.21776/ub.biotropika.2024.012.02.03Keywords:
isorhamnetin, obesity, PPAR-?, kenituAbstract
Studies reported that kenitu (Chrysophyllum cainito) has the potential as an anti-obesity agent. However, the mechanism underlying that activity remains unknown. On the other hand, targeting PPAR-y has played a beneficial role in regulating obesity. Therefore, this study will explain the anti-obesity potential of natural compounds from C. cainito in modulating obesity through inhibition of PPAR-y. Molecular docking was employed to identify the possibility of several compounds binding with the PPAR-y. Moreover, the stability of the interaction between PPAR-y and each compound was also evaluated using molecular dynamics analysis. The result showed that beta-sitosterol, lupeol, myricitrin, quercitrin, rutin, vitamin A, epicatechin, and chlorogenic acid are worthy of potential as PPAR-y antagonists. In advance, molecular dynamics simulations revealed that chlorogenic acid, quercitrin, and epicatechin were the most stable compounds to interact as an inhibitor of PPAR-y. In conclusion, compounds from star apple have some potential to improve the health status of patients’ obesity through PPAR-y antagonist activity.
References
Cardel MI, Atkinson MA, Taveras EM, Holm JC, Kelly AS (2020) Obesity treatment among adolescents: a review of current evidence and future directions. JAMA Pediatr 174(6): 609–617. doi: 10.1001/jamapediatrics.2020.0085.
Endalifer ML, Diress G (2020) Epidemiology, predisposing factors, biomarkers, and prevention mechanism of obesity: a systematic review. Journal of Obesity 2020(4): 1-8. doi: 10.1155/2020/61343 62.
Sangaji N, Wiyono VH, Mulyaningsih T (2022) Socio-economic determinants of obesity in Indonesia: analysis of IFLS 2014 data. Budapest International Research and Critics Institute (BIRCI-Journal): Humanities and Social Sciences 5 (1): 1939–1947. doi: 10.332 58/birci.v5i1.3794.
Malik VS, Willet WC, Hu FB (2020) Nearly a decade on — trends, risk factors and policy implications in global obesity. Nat Rev Endocrinol 16 (11): 615–616. doi: 10.1038 /s41574-020-00411-y.
Sharma SP, Chung HJ, Kim HJ, Hong ST (2016) Paradoxical Effects of Fruit on Obesity. Nutrients 8(10): 633. doi: 10.3390/ nu8100633.
Alinia S, Hels O, Tetens I (2009) The potential association between fruit intake and body weight--a review. Obes Rev 10(6):639–647. doi: 10.1111/j.1467789X.2009.00582.x.
Hebden L, O’Leary F, Rangan A, Singgih Lie E, Hirani V, Allman-Farinelli M (2017) Fruit consumption and adiposity status in adults: A systematic review of current evidence. Crit Rev Food Sci Nutr 57(12): 2526–2540. doi: 10.1080/10408398.2015.1012290.
Guyenet SJ (2022) Impact of Whole, Fresh Fruit Consumption on Energy Intake and Adiposity: A Systematic Review, Frontiers in Nutrition 6(66): 1-19. doi: 10.3389/fnut.2019.00066.
Doan HV, Le TP (2020) Chrysophyllum cainito: A Tropical Fruit with Multiple Health Benefits. Evidence-Based Complementary and Alternative Medicine 2020(7259267): 1-9. doi: 10.1155/2020/7259267.
Briones AT, Chichioco-Hernandez CL (2017) Lipase inhibitory activity of Carica papaya, Chrysophyllum cainito, Corcorus olitorius, Cympogon citrates and Syzygium cumini extracts. Food Res 2(1): 51–55. doi: 10.26656/fr.2017.2(1).118.
Aumeeruddy M Z, Mahomoodally MF (2021) Traditional herbal medicines used in obesity management: a systematic review of ethnomedicinal surveys. Journal of Herbal Medicine 28 (2999): 1-22. doi: 10.1016/j.hermed.2021.100435.
Alonso-Castro AJ, Domínguez F, Zapata-Morales JR, Carranza-Álvarez C (2015) Plants used in the traditional medicine of Mesoamerica (Mexico and Central America) and the Caribbean for the treatment of obesity. Journal of Ethnopharmacology 175(15): 335–345. doi: org/10.1016/j.jep.2015.09.029.
Lailiyah NN, Ibrahim MD, Fitriani CA, Hermanto FE (2021) Anti-obesity properties of black pepper (Piper nigrum): completing puzzle using computational analysis. JSMARTech 2(3): 101–106. doi: 10.21776/ub.jsmartech.2021.002.03.101
Liu TT, Liu XT, Chen QX, Shi Y (2020) Lipase inhibitors for obesity: a review. Biomedicine & Pharmacotherapy 128 (110314): 1-9. doi: 10.1016/j.biopha.2020. 110314.
Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W (2002) A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16(11): 2628–2644. doi: 10.1210/me.2002003 6.
Goto T, Kim YI, Takahashi N, Kawada T (2013) Natural compounds regulate energy metabolism by the modulating the activity of lipid-sensing nuclear receptors. Mol Nutr Food Res 57(1): 20–33. doi: 10.1002/mnfr. 201200522.
Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang M W, Peng L, Zang Y Q (2009) The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 150(1): 104–113. doi: 10. 1210/en.2008 -0322.
Wang S, Lin Y, Gao L, Yang Z, Lin J, Ren S, Li F, Chen J, Wang Z, Dong Z, Sun P, Wu B (2022) PPAR-? integrates obesity and adipocyte clock through epigenetic regulation of Bmal1. Theranostics 12(4): 1589–1606. doi: 10.7150/thno.69054.
Choi JH, Banks AS, Estall JL, Kajimura S, Bostrom P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bluher M, Griffin PR, Spiegelman BM (2010) Obesity-linked phosphorylation of PPAR? by cdk5 is a direct target of the anti-diabetic PPAR? ligands. Nature 466(7305): 451–456. doi: 10.1038 /nature09291.
Hogh KLN, Craig MN, Uy CE, Nygren H, Asadi A, Speck M, Fraser JD, Rudecki AP, Baker RK, Oreši? M, Gray SL (2014) Overexpression of PPAR? specifically in pancreatic ?-cells exacerbates obesity-induced glucose intolerance, reduces ?-cell mass, and alters islet lipid metabolism in male mice. Endocrinology 155 (10): 3843–3852. doi: 10.1210/en.2014-1076.
Zhang Y, Gu M, Cai W, Yu L, Feng L, Zhang L, Zang Q, Wang Y, Wang D, Chen H, Tong Q, Ji G, Huang C (2016) Dietary component isorhamnetin is a PPAR? antagonist and ameliorates metabolic disorders induced by diet or leptin deficiency. Sci Rep 6(1): 1-13. doi: 10.1038/srep19288.
Dallakyan S, Olson AJ (2015) Small-molecule library screening by docking with PyRx. Methods in Molecular Biology 1263: 243–250. doi: 10.1007/978-1-4939-2269-7_19.
Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 31(2): 455–461. doi: 10.1002/ jcc.21334.
Schüttelkopf AW, van Aalten DMF (2004) PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr 60(8): 1355–1363. doi: 10.1107/S090744490 4011679.
Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, Lindahl E (2015) GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1–2 (2015): 19–25. doi: 10.1016/j.softx.2015.06.001.
Oostenbrink C, Villa A, Mark AE, van Gunsteren WF (2004) A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem 25(13): 1656–1676. doi: 10.1002/jcc.20090.
Li SZ, Zeng SL, Liu EH (2022) Anti-obesity natural products and gut microbiota. Food Research International 151(2022) 110819: 1-14. doi: 10.1016/j.foodres.2021.110819.
Boccellino M, D’Angelo S (2020) Anti-obesity effects of polyphenol intake: current status and future possibilities. Int J Mol Sci 21 (16): 1-24. doi: 10.3390/ijms21165642.
Meng XY, Zhang HX, Mezei M, Cui M (2011) Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 7 (2): 146–157. doi: 10.2174/157340911795677602.
Fu Y, Zhao J, Chen Z (2018) Insights into the molecular mechanisms of protein-ligand interactions by molecular docking and molecular dynamics simulation: a case of oligopeptide binding protein. Comput Math Methods Med 2018 (3502514): 1-12. doi: 10.1155/2018/3502514.
Sargsyan K, Grauffel C, Lim C (2017) How molecular size impacts RMSD applications in molecular dynamics simulations. J Chem Theory Comput 13: 1518–1524. doi: 10.1021/acs.jctc.7b00028.
Liu K, Kokubo H (2017) Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: a cross-docking study. J. Chem. Inf. Model 57: 2514–2522. doi: 10.1021/acs.jcim.7b00412.
Yun S, Guy HR (2011) Stability tests on known and misfolded structures with discrete and all atom molecular dynamics simulations. J Mol Graph Model 29: 663–675. doi: 10.1016/j.jmgm.2010.12.002.
Shen Y, Chi H, Zhou J, Luo L, Tu Q, Qi C, Gao Z (2019) Structure-based stepwise screening of PPAR? antagonists as potential competitors with NCOA1 coactivator peptide for PPAR? CIS site. International Journal of Peptide Research and Therapeutics 25(4): 1369-1377. doi: 10.1007/s10989-018-9782-x.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Biotropika: Journal of Tropical Biology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright and Attribution:
Articles in Biotropika: Journal of Tropical Biology are under Creative Commons Attribution-NonCommercial (CC-BY-NC) copyright. The work has not been published before (except in the form of an abstract or part of a published lecture or thesis) and it is not under consideration for publication elsewhere. When the manuscript is accepted for publication in this journal, the authors agree to the automatic transfer of the copyright to the publisher.
Journal of Biotropika: Journal of Tropical Biology is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
Permissions:
Authors wishing to include figures, tables, or text passages that have already been published elsewhere and by other authors are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from one of the authors.
Ethical matters:
Experiments with animals or involving human patients must have had prior approval from the appropriate ethics committee. A statement to this effect should be provided within the text at the appropriate place. Experiments involving plants or microorganisms taken from countries other than the author's own must have had the correct authorization for this exportation.
